MacroGenics, Inc. (MGNX)

NASDAQ: MGNX · IEX Real-Time Price · USD
7.12
+0.43 (6.43%)
At close: Mar 21, 2023, 4:00 PM
7.22
+0.10 (1.40%)
After-hours: Mar 21, 2023, 5:18 PM EDT
6.43%
Market Cap 462.80M
Revenue (ttm) 151.94M
Net Income (ttm) -119.76M
Shares Out 65.00M
EPS (ttm) -1.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 802,236
Open 6.87
Previous Close 6.69
Day's Range 6.80 - 7.36
52-Week Range 2.13 - 10.20
Beta 1.95
Analysts Buy
Price Target 10.61 (+49.02%)
Earnings Date May 2, 2023

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugat... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2013
Employees 427
Stock Exchange NASDAQ
Ticker Symbol MGNX
Full Company Profile

Financial Performance

In 2022, MacroGenics's revenue was $151.94 million, an increase of 96.19% compared to the previous year's $77.45 million. Losses were -$119.76 million, -40.75% less than in 2021.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price forecast is $10.61, which is an increase of 49.02% from the latest price.

Price Target
$10.61
(49.02% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MacroGenics (MGNX) Surpasses Q4 Earnings Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 170% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

MacroGenics Provides Corporate Update and 2022 Financial Results

ROCKVILLE, Md., March 15, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

6 days ago - GlobeNewsWire

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix's linker-payload technologies Expanded collaboration incl...

1 week ago - PRNewsWire

MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

1 week ago - GlobeNewsWire

MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

1 week ago - GlobeNewsWire

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

2 weeks ago - GlobeNewsWire

Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?

MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

1 month ago - Zacks Investment Research

MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium

ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu...

1 month ago - GlobeNewsWire

MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

2 months ago - GlobeNewsWire

MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors

ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

2 months ago - GlobeNewsWire

Can MacroGenics (MGNX) Climb 74% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 73.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the po...

3 months ago - Zacks Investment Research

Buy These 3 Top Stocks for Solid Earnings Acceleration

Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & Euronav (EURN) at the moment for superb earnings acceleration.

Other symbols: EURNNRDS
3 months ago - Zacks Investment Research

MacroGenics (MGNX) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

3 months ago - Zacks Investment Research

Here's How to Find Cheap Stocks Under $10 to Buy for December

Use one of our Zacks screens to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying heading into December and beyond

Other symbols: NINE
4 months ago - Zacks Investment Research

MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab

ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th...

4 months ago - GlobeNewsWire

Wall Street Analysts Believe MacroGenics (MGNX) Could Rally 123%: Here's is How to Trade

The consensus price target hints at a 122.6% upside potential for MacroGenics (MGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti...

4 months ago - Zacks Investment Research

5 Best Stocks to Invest in for Solid Earnings Acceleration

Invest in stocks like MacroGenics (MGNX), NerdWallet (NRDS) & LivePerson (LPSN) at the moment for superb earnings acceleration.

Other symbols: LPSNNRDSOLKRAMP
4 months ago - Zacks Investment Research

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results

ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the...

4 months ago - GlobeNewsWire

Wall Street Analysts See a 279% Upside in MacroGenics (MGNX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 278.9% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the p...

5 months ago - Zacks Investment Research

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut...

5 months ago - GlobeNewsWire

MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies

FOSTER CITY, Calif.

Other symbols: GILD
5 months ago - Business Wire

Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 291% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the pos...

7 months ago - Zacks Investment Research

MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 30.93% and 78.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research